Long-term tamoxifen citrate use and potential ocular toxicity

American Journal of Ophthalmology

Volumn 125, Issue 4, 1998, Pages 493-501

  Gorin, Michael B ^a   Day, Richard ^b   Costantino, Joseph P ^b   Fisher, Bernard ^c   Redmond, Carol K ^b   Wickerham, Lawrence ^c   Gomolin, Julius E S ^d   Margolese, Richard G ^d   Mathen, Mathen K ^e   Bowman, David M ^e   Kaufmann, David ^f   Dimitrov, Nikolay V ^f   Singerman, Lawrence J ^g,h   Bornstein, Richard ^g   Wolmark, Norman ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Allegheny University   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g Mt Sinai Medical Center Cleveland   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN CITRATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG USE; EYE TOXICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0032052179     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(99)80190-1     Document Type: Article

References (30)

1. 1. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease: a review. J Clin Oncol 1996;14:1018-1026.
2. 2. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-484.
3. 3. Fisher B, Redmond C, Wickerham DL, et al. Systemic therapy in patients with node-negative breast cancer: a commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Ann Intern Med 1989;111:703-712.
4. 4. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
5. 5. Mangione CM, Phillips RS, Seddon JM, et al. Development of the 'Activities of Daily Vision Scale': a measure of visual functional status. Med Care 1992;30:1111-1126.
6. 6. Ferris FL, Kassoff A, Bresnick GH, Bailery I. New visual acuity charts for clinical research. Am J Ophthalmol 1987; 94:91-96.
7. 7. Bowman KJ. A method for quantitative scoring of the Farnsworth panel D-15. Acta Ophthalmol (Copenh) 1982; 60:907-916.
8. 8. Schneck ME, Haegerstrom-Portnoy G, Brabyn J, Katz B. SKILL card: hidden deficits in 'recovered' optic neuritis. ARVO abstracts. Invest Ophthalmol Vis Sci 1992; 33(4,suppl):964.
9. 9. Enger C, Sommer A. Recognizing glaucomatous field loss with the Humphrey STATPAC. Arch Ophthalmol 1987;105: 1355-1357.
10. 10. Katz J, Sommer A, Gaasterland DE, Anderson DR. Comparison of analytic algorithms for detecting glaucomatous visual field loss. Arch Ophthalmol 1991;109:1684-1689.
11. 11. McKeown C, Swartz M, Blom J, Maggiano J. Tamoxifen retinopathy. Br J Ophthalmol 1981;65:177-179.
12. 12. Chang T, Gonder J, Ventresca M. Low-dose tamoxifen retinopathy. Can J Ophthalmol 1992;27:148-149.
13. 13. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995;39:367-374.
14. 14. Chylack LT Jr, Wolfe JK, Singer DM, et al, for the Longitudinal Study of Cataract Study Group. The Lens Opacities Classification System III. Arch Ophthalmol 1993;111: 831-836.
15. 15. Chylack LJ, Wolfe JK, Friend J, et al. Validation of methods for the assessment of cataract progression in the Roche European-American Anticataract Trial (REAQ). Ophthalmic Epidemiol 1995;2:59-75.
16. 16. Mecca E, Tovena G, Marchini G, et al. Study of color perception using a new color test and desaturated panel D-15 in normal subjects and diabetics. J Fr Ophtalmol 1988;11: 493-500.
17. 17. Brinchmann HO, Bangstad HJ, Hultgren S, et al. Psychophysical visual function, retinopathy, and glycemic control in insulin-dependent diabetics with normal visual acuity. Acta Ophthalmol (Copenh) 1993;71:230-237.
18. 18. Banford D, North RV, Dolben J, Butler G, Owens DR. Longitudinal study of visual functions in young insulin dependent diabetics. Ophthalmic Physiol Opt 1994; 14: 339-346.
19. 19. Bowman KJ. The clinical assessment of colour discrimination in senile macular degeneration. Acta Ophthalmol (Copenh) 1980;58:337-346.
20. 20. Bowman KJ. The relationship between color discrimination and visual acuity in senile macular degeneration. Am J Optom Physiol Opt 1980;57:145-148.
21. 21. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993;53:3919-3924.
22. 22. Zhang JJ, Jacob TJC, Valverde MA, et al. Tamoxifen blocks chloride channels. J Clin Invest 1994;94:1690-1697.
23. 23. Cumming RG, Mitchell P. Hormone replacement therapy, reproductive factors, and cataract: the Blue Mountains Eye Study. Am J Epidemiol 1997;145:242-249.
24. 24. Pavlidis N, Petris C, Briassoulis E, et al. Clear evidence that long-term low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992;69:2961-2964.
25. 25. Heier JS, Dragoo RA, Enzenauer RW, et al. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994;117:772-775.
26. 26. Locher D, Tang R, Pardo G, Hamlin M. Retinal changes associated with tamoxifen treatment for breast cancer. ARVO abstracts. Invest Ophthalmol Vis Sci 1994;35 (4,suppl):1526.
27. 27. Kaiser-Kupfer M, Lippman M. Tamoxifen retinopathy. Cancer Treat Rep 1978;62:315-320.
28. 28. Vinding T, Nielsen N. Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol (Copenh) 1983; 61:45-50.
29. 29. Werblin TP, Hirst LW, Stark WJ, Maumenee IH. Prevalence of map-dot-fingerprint changes in the cornea. Br J Ophthalmol 1981;65:401-409.
30. 30. Renfro L, Snow JS. Ocular effects of topical and systemic corticosteroids. Dermatol Clin 1992;10:505-512.